Previous Close | 14.12 |
Open | 14.00 |
Bid | 12.00 x 1100 |
Ask | 14.21 x 1300 |
Day's Range | 13.50 - 14.55 |
52 Week Range | 8.05 - 17.25 |
Volume | |
Avg. Volume | 61,733 |
Market Cap | 81.529M |
Beta (5Y Monthly) | 1.00 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.52 |
Earnings Date | Mar 15, 2023 - Mar 20, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 40.17 |
Subscribe to Yahoo Finance Plus to view Fair Value for MDWD
The latest Consumer Price Index (CPI) figures showed that inflation is still easing, having dropped for the 6th consecutive month. The CPI for December rose by 6.5% from the same period a year ago and fell by 0.1% compared to November, thereby meeting Street expectations. There are still areas of concern, though, such as services inflation, which might put a spanner in the works for investors hoping the latest readout will cause the Fed to put the brakes on its rate-hiking endeavors. Additionall
This month, we saw the MediWound Ltd. ( NASDAQ:MDWD ) up an impressive 39%. But that is little comfort to those holding...
The FDA has approved MediWound Ltd's (NASDAQ: MDWD) NexoBrid (anacaulase-bcdb) to remove eschar in adults with deep partial-thickness and/or full-thickness thermal burns. NexoBrid, a botanical drug product containing proteolytic enzymes, is already approved in 43 countries. Recently, MediWound signed an agreement with Triskel Integrated Services to market and distribute NexoBrid in Switzerland, with a launch planned for Q1 of 2023. Triskel also holds the distribution rights of NexoBrid in France